Merck Animal Health Receives License Approval for CIRCUMVENT® CML Vaccine
Vaccine effective against disease caused by Porcine Circovirus Types 2a and 2d, Mycoplasma hyopneumoniae and Lawsonia intracellularis in pigs, three weeks of age and older
MADISON, N.J., June 8, 2022 – Merck Animal Health, known as MSD Animal Health outside the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), announced today it has received license approval for Circumvent® CML vaccine in the U.S. from the Department of Agriculture (USDA).
Circumvent® CML is the first-ready-to-use, single-dose vaccine effective against disease caused by Porcine Circovirus Types 2a and 2d, Mycoplasma hyopneumoniae and Lawsonia intracellularis in pigs, three weeks of age or older.
“Merck Animal Health is excited to bring this important innovation to our customers as part of our commitment to offering comprehensive solutions for improved animal health outcomes,” said Jamie Lehman, D.V.M., Swine Technical Services Veterinarian, Merck Animal Health. “This vaccine nicely complements Circumvent® PCV G2, PCV-M G2 and Porcilis Ileitis product portfolio, providing swine veterinarians and producers the additional option of vaccinating against disease caused by PCV2, Mycoplasma hyopneumoniae and Lawsonia intracellularis all in one bottle.”
Circumvent® CML will be commercially available starting in early 2023. It will come in 50-ml, 250-ml, and eventually, 500-ml dose presentations.
To learn more about our portfolio of swine health products and vaccines, visit www.drivenbyprevention.com.
CIRCUMVENT® CML PRODUCT LABEL https://cvpln.com/mrk/nzsdj4X4
About Merck Animal Health
At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than a century, we’ve been at the forefront of research, bringing forward medicines, vaccines and innovative health solutions for the world’s most challenging diseases. Merck Animal Health, a division of Merck & Co., Inc., Rahway, N.J., USA, is the global animal health business unit of Merck. Through its commitment to The Science of Healthier Animals®, Merck Animal Health offers veterinarians, farmers, pet owners and governments one of the widest ranges of veterinary pharmaceuticals, vaccines and health management solutions and services as well as an extensive suite of connected technology that includes identification, traceability and monitoring products. Merck Animal Health is dedicated to preserving and improving the health, well-being and performance of animals and the people who care for them. It invests extensively in dynamic and comprehensive R&D resources and a modern, global supply chain. Merck Animal Health is present in more than 50 countries, while its products are available in some 150 markets. For more information, visit www.merck-animal-health.com and connect with us on LinkedIn, Facebook, Twitter and Instagram.
| Media Contact: | Kathleen Cuddy | ||
| (816) 301-8253 Kathleen.cuddy@merck.com |